LQT1-1781G/A hiPSC, LUMC0021iKCNQ-30
LUMCi039-A
General
Cell Line |
|
| hPSCreg name | LUMCi039-A |
| Cite as: | LUMCi039-A (RRID:CVCL_A7QT) |
| Alternative name(s) |
LQT1-1781G/A hiPSC, LUMC0021iKCNQ-30
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
TAUi006-A (UTA.00102.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi006-B (UTA.00118.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi007-A (UTA.00208.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi007-B (UTA.00211.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 UKKi034-A (NP0079-A, NP0079-7B) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Familial long QT syndrome UKKi034-B (NP0079-B, NP0079-15B) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Familial long QT syndrome UKKi034-C (NP0079-C, NP0079-16H) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Familial long QT syndrome HDZi001-A (hiPSC NP0039) Donor's gene variants: TMEM43 Donor diseases: arrhythmogenic right ventricular dysplasia 5 |
| Last update | 15th December 2021 |
| User feedback | |
Provider |
|
| Generator |
Leiden University Medical Center (LUMC)
Contact:
LUMC hiPSC core facility |
| Owner | Leiden University Medical Center (LUMC) |
| Distributors | |
| Derivation country | Netherlands |
External Databases |
|
| BioSamples | SAMEA8307098 |
| Cellosaurus | CVCL_A7QT |
| Wikidata | Q107115879 |
General Information |
|
| Publications |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA8307101 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | Yes |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | through the responsible physician at LUMC |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | Yes |
| Contact data, institution, or website: | through the responsible physician at LUMC |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Leiden University Medical Centre ethics committee |
| Approval number | P 13.080 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Leiden University Medical Centre ethics committee |
| Approval number | P 13.080 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | M. Ohtaka, K. Nishimura, and M. Nakanishi (National Institute of Advanced Industrial Science and Technology, Japan) |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
| Source cell origin |
An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
Immunostaining, RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Morphology and proliferation, pluripotent |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin |
| Feeder cells |
Mouse embryonic feeder cells |
| Passage method | Mechanically |
| Medium |
Other medium:
Base medium: DMEM-F12
Main protein source: Knock-out serum replacement Serum concentration: 20 % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| TRA 1-81 |
Yes |
|||||
| NANOG |
Yes |
|
||||
| SSEA-4 |
Yes |
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
| Pluripotency Score | Novelty Score | |
| 32.34 | 1.38 |
Report
Pluritest.pdf
Pluritest output
Morphology pictures
Morphology_colony.pdf
hiPSC colony on MEFs - bright field
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| AFP |
Yes |
Morphology
AFP - endoderm.pdf
AFP IF staining
In vitro spontaneous differentiation
| Marker | Expressed |
| CD31 |
Yes |
Morphology
CD31 - mesoderm.pdf
CD31 IF staining
In vitro spontaneous differentiation
| Marker | Expressed |
| Beta 3 Tubulin |
Yes |
Morphology
TUBB3 - ectoderm.pdf
TUBB3 IF staining
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.